Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400516 | 1.00 | KMT2A (0.55) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL503436 | 1.00 | KMT2A (0.55) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL11081241 | 0.85 | CA12 (0.47) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL2461228 | 0.85 | KDM4E (0.50) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL2461230 | 0.85 | KDM4E (0.50) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL4697541 | 0.85 | FABP4 (0.48) | KMT2ANPSR1POLBHTTL3MBTL1 | |
| SCHEMBL1354214 | 0.85 | PTGS2 (0.55) | TSHRBLMFABP4FABP5LMNA | |
| SCHEMBL14800030 | 0.85 | PTGS2 (0.55) | TSHRBLMFABP4FABP5LMNA | |
| SCHEMBL5171115 | 0.85 | PTGS2 (0.55) | TSHRBLMFABP4FABP5LMNA | |
| SCHEMBL13170107 | 0.84 | POLB (0.49) | KMT2ANPSR1POLBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109467502-B | Method for splitting mandelic acid compound enantiomer | 湖南科技大学 | 2021-07-30 | — | — | CN | claimed |
| EP-1358144-B1 | EPOTHILONE SYNTHESIS COMPONENTS I: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE AND EPOTHILONE DERIVATIVES | R & D BIOPHARMACEUTICALS (DE) | 2006-12-27 | — | — | EP | claimed |
| US-6867333-B2 | EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2005-03-15 | — | — | US | claimed |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | R & D BIOPHARMACEUTICALS GMBH (DE) | 2004-04-29 | — | — | US | claimed |
| EP-1358144-A1 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | Morphochem AG (DE) | 2003-11-05 | — | — | EP | claimed |
| WO-2002032844-A2 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2002-04-25 | — | — | WO | claimed |
| CN-108047033-B | Reaction device and method for preparing mandelic acid compound | 江西科苑生物药业有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-109467502-B | Method for splitting mandelic acid compound enantiomer | 湖南科技大学 | 2021-07-30 | — | — | CN | disclosed |
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10745412-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-102603694-B | Novel synthesis method of murrayone and novel application of murrayone | GANNAN MEDICAL UNIVERSITY | 2014-06-25 | — | — | CN | disclosed |
| CN-101854907-B | Cosmetic composition comprising hydroxymethionine and 3-aminopropanesulfonic acid | SEDERMA SA | 2014-06-18 | — | — | CN | disclosed |
| US-4126468-A | Radiation sensitive compositions of quaternary ammonium salt and carboxylic acid sensitizer | VICKERS LIMITED (GB) | 1978-11-21 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4018759-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1977-04-19 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3957768-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3946005-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
| US-3943129-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | ACACA, ACACB, ACAT2 | KMT2A 2681/4885NPSR1 4672/4885POLB 1076/4885 |
| US-10745412-B2 | Processes for preparing ACC inhibitors and solid forms thereof | ACACA, ACACB, ACAT2 | KMT2A 2681/4885NPSR1 4672/4885POLB 1076/4885 |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | COASY, ACOX1, FDFT1 | KMT2A 1787/4885NPSR1 3404/4885POLB 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.